The Clinical Efficacy Of Treatment Of Hematologic Malignancies Over 50 Years Old With Reduced Intensity Conditioning Regimen In Related HLA Haploidentical Non T Cell-Depleted In Vitro PBSCT

Objective:To evaluate the clinical efficacy of reduced intensity conditioning related received HLA haploidentical non T cell-depleted in vitro PBSCT(RIC-RH-P BSCT)in the treatment of hematologic malignancies which over 50 years old.Methods:From January 2013 to February 2018,14 patients with the malignant hematological neoplasms were treated with RIC-RH-PBSCT in the hematologic center of the First Affiliated Hospital of Xinjiang Medical University.14 patients achieved sustained myeloid engraftment,high dose of simple peripheral blood stem cell infused:mononuclear cells(MNC)was 14.82(9.05-19.84)×10~8/kg,CD34~+cell median:6.41(3.03-17.81)×10~6/kg;Observe about the early engraftment?recovery of hematopoietic function?graft-versus-host disease,NRM,RR,DFS,OS,etc.Results:Neutroil was 16(12-29)days,16(10-34)days of Platelet.The cumulative incidence of acute graft-versus-host disease(aGVHD)was 57.1%.The incidence of II-IV was 21.4%,and the incidence of III-IV was 7.1%.The incidence of chronic graft-versus-host disease(cGVHD)is 33.3%,which is limited.The incidence of infection in 100 days and 180 days after transplantation was 50.0%and 60.8%,respectively.The median follow-up period was 7.5(3-36)months,the 1-year estimated overall survival(OS)was 67.0%,and the disease-free survival(DFS)was 53.6%.The relapse rate(RR)in 1 year was 37.0%,and the None-relapse mortality(NRM)in 1 year was 14.9%.The total chimerism rate was 85.7%and the mixed chimerism was2.Conclusion:the unique RIC-RH-PBSCT transplantation scheme in our center is benefit for the treatment of hematologic malignancies in the elderly,and the transplantation model is feasible.